Effects of treatment with Sandostatin LAR on small dense LDL and remnant-like lipoproteins in patients with acromegaly.
OBJECTIVE
Acromegalic patients have been shown to have an increase in the concentrations of small dense low-density lipoprotein (LDL) and remnant-like lipoprotein particles (RLP). These lipoproteins are atherogenic and may contribute to the cardiovascular risk of these patients. The aim of this study was to determine whether treatment of acromegaly using Sandostatin LAR could lower these atherogenic lipoproteins.


METHODS
Fourteen patients with active acromegaly were recruited and Sandostatin LAR, a long-acting somatostatin analogue, was given every 4 weeks by intramuscular injection for 6 months. Fasting lipids, lipoproteins, lipolytic enzymes were determined at baseline, 12 and 24 weeks after treatment. Small dense LDL was measured using density gradient ultracentrifugation and RLP-cholesterol (RLP-C) by an immunoseparation assay.


RESULTS
There was already a marked reduction in GH and IGF-1 by week 8 and, in all subjects, IGF-1 levels within their respective age-specific normal range were achieved. At week 12, plasma triglyceride significantly decreased (P < 0.01) and both HDL2 (P < 0.01) and HDL3 (P < 0.01) subfractions increased. A reduction was seen in small dense LDL concentration (P < 0.05) and RLP-C (P < 0.05). Lipoprotein lipase (LPL) activity increased (P < 0.01) and the magnitude of the increase in LPL activity correlated with the increase in HDL at 3 months (r = 0.55, P < 0.05) but not with the changes in plasma triglyceride, small dense LDL or RLP-C. The improvement in plasma lipids and lipoproteins persisted until the end of the study.


CONCLUSIONS
Sandostatin LAR is effective in the treatment of acromegaly and is associated with favourable changes in plasma lipids and a reduction in small dense LDL and RLP-C.
Tan
K C B
KC
Department of Medicine, University of Hong Kong, Queen Elizabeth Hospital, Hong Kong. kcbtan@hkucc.hku.hk
Pang
R W C
RW
Tiu
S C
SC
Lam
K S L
KS
D000172:Acromegaly / Q000188:drug therapy*; D000328:Adult; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use*; D016632:Apolipoprotein A-I / Q000032:analysis; D001786:Blood Glucose / Q000032:analysis; D002784:Cholesterol / Q000097:blood; D003692:Delayed-Action Preparations; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D019382:Human Growth Hormone / Q000097:blood; D006801:Humans; D007328:Insulin / Q000097:blood; D007334:Insulin-Like Growth Factor I / Q000032:analysis; D008074:Lipoproteins / Q000097:blood; D008075:Lipoproteins, HDL / Q000097:blood; D008077:Lipoproteins, LDL / Q000097:blood*; D008297:Male; D008875:Middle Aged; D015282:Octreotide / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood
D018931:Antineoplastic Agents, Hormonal; D016632:Apolipoprotein A-I; D001786:Blood Glucose; D002784:Cholesterol; D003692:Delayed-Action Preparations; D006442:Glycated Hemoglobin; D019382:Human Growth Hormone; D007328:Insulin; D007334:Insulin-Like Growth Factor I; D008074:Lipoproteins; D008075:Lipoproteins, HDL; D008077:Lipoproteins, LDL; D015282:Octreotide; D014280:Triglycerides; C112017:remnant-like particle cholesterol